China SXT Pharmaceuticals, Inc. (SXTC) Operating cash flow 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$4.0MFY2026 · since FY2017: $293,042 → -$4.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$4.0M | -71.3% |
| FY2025 | -$2.3M | -21.6% |
| FY2024 | -$1.9M | -2287.5% |
| FY2023 | -$80,757 | -130.1% |
| FY2022 | $268,293 | +120.4% |
| FY2021 | -$1.3M | -240.9% |
| FY2020 | $934,247 | +290.6% |
| FY2019 | $239,192 | -87.5% |
| FY2018 | $1.9M | +555.3% |
| FY2017 | $293,042 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →